VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) IN DR. WAHIDIN SUDIROHUSODO HOSPITAL MAKASSAR

Fatmawaty Ahmad, Nurhayana Sennang, Benny Rusli

Abstract


Vancomycin Resistant Staphylococcus aureus (VRSA) refers to bacteria that have complete resistance to Vancomycin. The increasing prevalence of VRSA can be a significant clinical problem with the limited therapeutic options. Therefore, the identification of  VRSA is necessary to improve the management of antibiotic therapy, infection control and to prevent the occurrence of wider resistance. This retrospective descriptive study used secondary data of antibiotic susceptibility test on Staphylococcus aureus identified using VITEK 2 and patient medical records from January 2015 to December 2016. The data is processed using SPSS. Of 387 Staphylococcus aureus isolates obtained, 45 (11%) were VRSA. The most common VRSA isolates were male patients (57.8%) with the mean age being 41-60 years old (35.6%). The treatment ward with the most VRSA isolates were from surgical ward (20%), and internal medicine ward (15.6%) whereas the  VRSA isolates from outpatient record were from surgical  department (8.9%), dermatology department and ENT department (2.2%). The most common specimens were blood (28.9%), pus (26.7%), and sputum (20.0%). The highest prevalence of VRSA was found in the use of ≥ 3 invasive medical devices and from clinical outcome was found 11 (24.4%) of the patients died. Linezolid, Quinupristin / Dalfopristin, Tigecycline, and Nitrofurantoin as a therapeutic option have > 90% sensitivity. Identification of  VRSA in Dr. Wahidin Sudirohusodo Hospital Makassar emphasized the need for  immediate action by infection control division, especially in related units to prevent the transmission.


Keywords


Staphylococcus aureus, Vancomycin, VRSA, Makassar

Full Text:

PDF

References


Finks J, Wells E, Dyke TL, et al. Vancomycin-Resistant Staphylococcus aureus,Michigan, USA, 2007. Emerging Infectious Diseases Journal. 2009; 943-945

Afifurrahman, K Husni S, Syahril A. Pola Kepekaan Bakteri Staphylococcus aureus terhadap Antibiotik Vancomycin di RSUP Dr. Mohammad Hoesin Palembang. Majalah Kedokteran Sriwijaya. 2014; 259-265

Moses A, Uchenna U, Nworie O. Epidemiology of Vancomycin Resistant Staphyloccus Aureus among Clinical Isolates in a Tertiary Hospital in Abakaliki, Nigeria. American Journal of Epidemiology and Infectious Disease. 2013; 24-26

Holmes NE, Johnson PDR, Howden BP. Relationship between Vancomycin-Resistant Staphylococcus aureus, Vancomycin-Intermediate S. aureus, High Vancomycin MIC, and Outcome in Serious S. aureus Infections. Journal of Clinical Microbiology. 2012; 2548-2552

Tarai B, Das P, Kumar D. Recurrent Challenges for Clinicians: Emergence of Methicillin-Resistant Staphylococcus aureus, Vancomycin Resistance, and Current Treatment Options. J Lab Physicians. 2013;71–78

Walters M, Lonsway D, Kamile Rasheed K, et al. Investigation and Control of Vancomycin- Resistant Staphylococcus aureus (VRSA): 2015 Update. Centers for Disease Control and Prevention. 2015; 1-20

Saadat S, Solhjoo K, Nejad MJN, and Kazemi A. VanA and VanB Positive Vancomycin-resistant Staphylococcus aureus Among Clinical Isolates in Shiraz, South of Iran. Oman Medical Journal. 2014; 335-339

Wisconsin Bureau of Communicable Diseases and Emergency Response Communicable Diseases Epidemiology Section. Vancomycin-intermediate/resistant Staphylococcus aureus (VISA/VRSA). 2012. [cited at September 23, 2017]. Available at: http:// www.dhs.wisconsin.gov

Loomba PS, Taneja J, Mishra B. Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients. Journal of Global Infectious Diseases. 2010; 275-283




DOI: http://dx.doi.org/10.24293/ijcpml.v25i2.1385

Refbacks

  • There are currently no refbacks.